The traditional care team model places doctors in charge of the team, but this structure may not be the most effective for complex patients with social challenges and other issues, said Jeffrey Brenner, MD, executive director of the Camden Coalition of Healthcare Providers.
The traditional care team model places doctors in charge of the team, but this structure may not be the most effective for complex patients with social challenges and other issues, said Jeffrey Brenner, MD, executive director of the Camden Coalition of Healthcare Providers.
Transcript (slightly modified)
How should care teams be utilized to best care for high-need, high-cost patients?
What’s really become clear to all of us over the years is that this is not about one doc in a room, that traditional model that we have in care. This is a team-based structure, and you need a lot of different skills to take care of complicated patients. The other thing is that the underlying driver for a lot of these patients is mental health, addiction, social challenges.
We’ve really put doctors at the center of the care team, and there’s nothing about our training that would make that really make sense when you lay out what’s going on with these patients. Just by virtue of training, it probably puts social workers in charge of the team, and the doctors would be there to support them. If you look at how we’re trained, we’re technical experts with a very specific set of knowledge, but if the challenges facing the patient are biopsychosocial, of which the medical’s just a piece, there’s no reason why we should be in charge of teams, leading teams, leading these models.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More